Your SlideShare is downloading. ×
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Merck & CO
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Merck & CO

2,209

Published on

THIS DOCUMENT HAS THE PURPOSE OF PRESENT WHO IS MERCK, WHAT IT DOES AND ITS PROPOSALS FOR THE PRESENT AND FUTURE HEALTH PROBLEMS SUCH AS IVH, AIDS.

THIS DOCUMENT HAS THE PURPOSE OF PRESENT WHO IS MERCK, WHAT IT DOES AND ITS PROPOSALS FOR THE PRESENT AND FUTURE HEALTH PROBLEMS SUCH AS IVH, AIDS.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
2,209
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
78
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. THIS DOCUMENT HAS THE PURPOSE OFPRESENT WHO IS MERCK, WHAT IT DOESAND ITS PROPOSALS FOR THE PRESENTAND FUTURE HEALTH PROBLEMS SUCH ASIVH, AIDS.MERCK AS A COMPANY HAS HAD A BIGDEVELOPMENT IN THE PHARMACEUTICALMARKET, THING THAT IT HAS RAISED BY ITSINTEREST IN DISCOVER NEW MEDICINESAS SOON A POSSIBLE TO CONTROL ANDCURE THE ILLNESS THAT ARE RUNNINGWITH THE PEOPLE´S LIFE. ALEJANDRA CAROLINA OSSA JUAN SEBASTIAN BETANCUR M VANESSA LEON URIBE 06/10/2011
  • 2. 2 TABLA DE CONTENIDOMERCK ................................................................................................................................................................ 3 Our Vision ....................................................................................................................................................... 3 Our Mission .................................................................................................................................................... 3 What We Stand For ........................................................................................................................................ 3OUR HISTORY...................................................................................................................................................... 3ABOUT US ........................................................................................................................................................... 3OUR VALUES ....................................................................................................................................................... 5RESPONSIBILITY ETHICS AND TRANSPARENCY ................................................................................................... 7LEADERSHIP ........................................................................................................................................................ 7HOW WE OPERATE ............................................................................................................................................. 8CODE OF CONDUCT ............................................................................................................................................ 9COMPLIANCE ...................................................................................................................................................... 9OUR COMMITMENT TO PRIVACY ..................................................................................................................... 10VIEWS AND POSITIONS ..................................................................................................................................... 11ACCESS AND AFFORDABILITY ........................................................................................................................... 11HEALTHCARE REFORM ..................................................................................................................................... 12INNOVATION .................................................................................................................................................... 13QUALITY & SAFETY ........................................................................................................................................... 13SALES & MARKETING ........................................................................................................................................ 14RESPONSIBLE PUBLIC POLICY AND ADVOCACY ................................................................................................ 14ACCESS .............................................................................................................................................................. 15ENVIRONMENT ................................................................................................................................................. 15DISCOVERY AND DEVELOPMENT ...................................................................................................................... 16COMMUNITY: FIGHTING HIV/AIDS ................................................................................................................... 16 Report from the United Nations about the AIDS in the 2010 ...................................................................... 17 Graphic No. 1: The number of people surviving with HIV continues to increase due to life-prolonging treatments ................................................................................................................................................... 18 Graphic No. 2: Treatment for HIV and AIDS is widespread, but not enough to meet the goal of universal access by 2010 ............................................................................................................................................. 19 Graphic No. 3: Work is progressing steadily in reducing HIV transmission to newborns ............................ 20CONSUMER PRODUCTS .................................................................................................................................... 21 1. ISENTRESS® .......................................................................................................................................... 21 2. CRIXIVAN® ........................................................................................................................................... 22CONCLUSION .................................................................................................................................................... 22REFERENCES ..................................................................................................................................................... 23
  • 3. 3 MERCKOur VisionWe make a difference in the lives of people globally through ourinnovativemedicines, vaccines, and consumer health and animal products. We aspire to bethe best healthcare company in the world and are dedicated to providing leadinginnovations and solutions for tomorrow.Our MissionTo provide innovative, distinctive products and services that save and improvelives and satisfy customer needs, to be recognized as a great place to work, and toprovide investors with a superior rate of return.What We Stand For - Excellence in science and healthcare innovation, with an emphasis on addressing unmet medical needs. - Focus on patients and anticipating customers’ needs. - Commitment to expand access to our medicines and vaccines, and to improve global health. OUR HISTORYWeve done great things in the past. Today, were doing great things for the future.Merck and Schering-Plough merged in November 2009 to create a new company.Today, we are the second-largest healthcare company in the world. We also are aglobal leader in consumer products and animal care.Through the years, our researchers have helped to find new ways to treat andprevent illness - from the discovery of vitamin B1, to the first measles vaccine, tocold remedies and antacids, to the first statins to treat high cholesterol. Ourscientists also have helped develop many products to improve animal health,including vaccines and antibiotics. ABOUT US
  • 4. 4 TICKER MRK NAME The company is known as Merck in the United States and Canada. Everywhere else, we are known as MSD. Merck & Co., Inc. is the legal name and is listed on the New York Stock Exchange under the symbol "MRK." Merck is an innovative, global healthcare leader that is committed to improving health and well-being around the world. Our product offering categories include heart and respiratory health, infectious diseases, sun care and womens health. We continue to focus our research on conditions that affect millions of people around the world - diseases like Alzheimers, diabetes and cancer - DESCRIPTION while expanding our strengths in areas like vaccines and biologics. We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them. At Merck, were applying our global reach, financial strength and scientific excellence to do more of what were passionate about: improving health and improving lives. Merck. Be Well. EMPLOYEES Approximately 93,000 employees worldwide (as of 3/31/11)HEADQUARTERS Whitehouse Station, New Jersey BUSINESSES Pharmaceuticals Alliances Consumer Care Animal Health 2010 GAAP Merck $46.0 billion Revenue2010 REVENUES United States $20.2 billion MERCK Europe, Middle East and Africa $13.5 billion(By Geographic Japan $3.8 billion Region) Other $8.5 billion 2010 R&D Merck $11.0 billion EXPENSE Merck is a global health care company that delivers innovative
  • 5. 5 PRODUCTS health solutions through its prescription medicines, vaccines, biologic therapies, and consumer and animal health products. Kenneth C. Frazier, president and chief executive officer EXECUTIVE Richard S. Bowles III, Ph.D., executive vice president and chief COMMITTEE compliance officer Peter S. Kim, Ph.D., executive vice president and president, Merck Research Laboratories J. Chris Scalet, executive vice president, Global Services, and chief information officer Adam H. Schechter, president, Global Human Health Mervyn Turner, Ph.D., chief strategy officer and senior vice president, Emerging Markets R&D, Merck Research Laboratories Sources: Merck be well OUR VALUESAs an organization, our core values are driven by a desire to improve human life,achieve scientific excellence, operate with the highest standards of integrity,expand access to our products and employ a diverse workforce that valuescollaboration. - Improving human life Our business is preserving and improving human life. We also work to improve animal health. All of our actions must be measured by our success in achieving these goals. - Ethics & integrity We are committed to the highest standards of ethics and integrity. We are responsible to our customers, to Merck employees, to the environments we inhabit, and to the societies we serve worldwide.
  • 6. 6 In discharging our responsibilities, we do not take professional or ethical shortcuts. Our interactions with all segments of society must be transparent and reflect the high standards we profess.- Innovation We are dedicated to the highest level of scientific excellence. Our research is guided by a commitment to preserving human and animal health and the quality of life. We strive to identify the most critical needs of consumers and customers, and through continuous innovation we challenge ourselves to meet those needs.- Access for all We aspire to improve the health and wellness of people around the world by expanding access to our medicines and vaccines. Creating new therapies is only the first step in battling disease and promoting wellness on a global scale. Success can only be achieved when everyone who needs our medicines and vaccines can get them. In the United States and abroad, weve developed numerous programs to help improve access to our products so that all can benefit, wherever they live. One example of this situation is the donation of a medicine called MECTIZAN®T through the program of donation of MECTIZAN of MERCK to more than 30 countries around the world, such as Brazil, Colombia, Guatemala, Ecuador, Venezuela and Mexico.- Diversity & teamwork Our ability to excel depends on the integrity, knowledge, imagination, skill, diversity and teamwork of our employees. To this end, we work to create an environment of mutual respect, encouragement and teamwork. We reward commitment and performance and are responsive to the needs of our employees and their families.
  • 7. 7 RESPONSIBILITY ETHICS AND TRANSPARENCYBecause millions of people around the world depend on our products, we havehigh standards for how we should conduct ourselves as a company.Our chief compliance officer, who reports directly to the CEO, is responsible forensuring high ethical standards and compliance across our business globally. Thisincludes: making sure that the company complies with all applicable laws andregulations.Our Office of Ethics supports our commitment to the highest standards of ethicsand integrity in all of our business practices. We map out clear expectations foremployees and hold them accountable for their behavior. We also have a numberof mechanisms available such as an Ombudsman office and global AdviceLine tohelp counsel employees who face challenging situations.We also remain committed to operating openly and with integrity. We have takensignificant steps recently to improve transparency, committing to public disclosureof our financial support for third-party groups and for healthcare providers whospeak on behalf of Merck or our products. We also make sure that study results ofour marketed products-regardless of outcome-are made available quickly onClinicalTrials.gov. LEADERSHIPHow we govern ourselves as a company is as important as anything else we do.Good corporate governance benefits both our customers and our shareholders,and is essential to our long-term business success.For this reason, we devote considerable time and resources to making sure that:  our policies reflect our values and business goals;  we have an effective corporate governance structure; and  we are operating in a way that is open, honest and transparent.
  • 8. 8 HOW WE OPERATEOur goal is to lead the way to a healthier future. But we also care about how we getthere together.As a company whose products touch the lives and well being of people around theworld, we hold ourselves to a high standard. And we expect others to hold us tothat same high standard.Diversity at MerckWe also value the diverse contributions of our employees around the world, andare committed to creating a workplace that is open, welcome and respectful of allof our employees. “These values and principles are at the heart of who we are as a company.”Diversity is the power of differences. We believe that having a diverse, inclusiveworkforce and organization makes us a more innovative and agile company,attuned to the needs of our customers.Every day, we strive to create an inclusive workplace, where diverseperspectives are respected and all opinions matter:  Diversity is woven throughout our business practices and training strategy.  Our leaders are accountable for specific objectives related to diversity and inclusion. Results are measured in terms of individual, division and company-wide performance.  We provide equal employment opportunities to all qualified job applicants.  We cast a wide net in our search for talent, seeking qualified suppliers – large and small – from all segments of the business community. This includes minority-, women- and veteran-owned businesses.
  • 9. 9 CODE OF CONDUCTOur values and standards are the basis of our success. They always have been.They always will be.The people who use, recommend or prescribe our products have placed their trustin us. No matter how strong our reputation, we must re - earn that trust every dayby practicing the values and standards that have guided this company for morethan 100 years.Our code of conduct, which we publish for employees under the title Our Valuesand Standards, helps to make sure that our employees understand what isexpected of them, and provides guidance on business standards and practices.This is just one of the many ways that we continually reinforce the values on whichthis company was built. COMPLIANCEBeing an ethical company is about much more than simply adhering to the letter ofthe law. But it’s an important step.As part of our long-standing commitment to ethics and good corporate citizenship,our first step is always to comply with the laws and regulations that govern the waywe market and sell our medicines, vaccines and other products.We have a well-established compliance program that:  is consistent with recommendations set forth by the U.S. Department of Health and Human Services and the Code on Interactions with Healthcare Professionals created by the Pharmaceutical Research and Manufacturers of America (PhRMA);  seeks to prevent, detect and resolve potential violations of law or company policy; and  undergoes regular assessment and adjustment to make sure we are being responsive to our evolving business and associated compliance risks.
  • 10. 10In addition, we:  require employees to report potential violations of law or company policy;  hold ourselves accountable for responding promptly when potential violations arise;  take disciplinary action as appropriate; and  examine whether identified violations are in part due to gaps in our policies, practices or internal controls and, if so, take appropriate action to prevent future violations.Our compliance program is just one part of our overall commitment to operatingethically, openly and transparently. But we believe it’s the right place to start. OUR COMMITMENT TO PRIVACYThe new Merck privacy program is built on a strong foundation of global privacypractices and standards and carries on our tradition of upholding high ethicalstandards in collecting, using and disclosing personal information across ourbusiness practices and in addressing privacy-related ethical issues in biomedicalresearch.Privacy Trust at Merck:We believe that trust is core to our privacy mission, so we have developed ourprivacy program around the following key elements of privacy trust: T - "transparency" - being open and clear about how we collect, use and disclose personal information R - "respecting choices" - such as whether or not people want to participate in our programs U - "understanding perspectives" - including that people have different levels of concern about their privacy based on cultural perspectives and personal experiences S - "security" - protecting personal information from loss, misuse and unauthorized access, disclosure, alteration or destruction
  • 11. 11 T - treating our stakeholders with respect and in a manner consistent with the Companys values VIEWS AND POSITIONSWe support public policies that advance the interests of patients, improve publichealth and promote access to medicines and innovation.We work to achieve our business objectives responsibly and respond to our manystakeholders needs and concerns. We support policies that promote the discoveryof innovative medicines and vaccines and make these products available to all whoneed them.To advance this objective, we:  develop policy positions that guide our activities and advocacy on a range of issues;  seek opportunities to adopt industry-leading standards in several areas;  strive to communicate clearly and transparently about our positions; and  work closely with the many groups and individuals who are also trying to address the complex healthcare challenges that confront us. ACCESS AND AFFORDABILITYThrough our business operations, public policy, and outreach efforts, we work toadopt progressive positions and advocate for change that will improve access tomedicines and vaccines, while balancing our ability to continue to developinnovative products to address healthcare needs.The issues related to access are varied and complex. Our approach seeks tocombine our strengths and abilities, working in close partnership with governments,donors, patient organizations, healthcare professionals, nongovernmentalorganizations, multilateral organizations, and others in the private sector.We are taking steps to advance this objective:
  • 12. 12Through a multi-pronged strategy, we are improving access to medicines andvaccines by examining our approach to research and development, manufacturingand supply, registration, commercialization, and community investment.In the developing world, including Africa and parts of Latin America and Asia, webelieve we have an important role and responsibility to help accelerate access toour medicines and vaccines where access is most lacking. Access is determinedby many interrelated elements – some countries may lack basic medicalinfrastructure, some patients may have limited access to hospitals or clinics, or insome places there may be shortages of trained healthcare personnel. We havetaken this into account in our own work and how we work with others. We engagein a wide range of public/private partnerships and other collaborations to spurprogress and new approaches to fighting diseases that affect the developing world,such as AIDS.In developed countries, access to medicines may be reduced by a lack ofaffordable healthcare coverage or long waiting times before innovative medicinesare approved or made broadly available. We believe greater access can beachieved through a strategy that combines the following:  pricing our products responsibly and, where necessary, donating our products to those who lack healthcare coverage, such as through our U.S. patient assistance programs;  advocating for healthcare reforms that will allow citizens greater access to treatment and care through programs such as Medicare in the United States. View our position on healthcare reform in the United States; and  promoting and participating in public/private partnerships to address chronic and infectious disease and other complex health challenges. HEALTHCARE REFORMMerck believes all Americans should have access to quality, affordable healthinsurance coverage. We are working to support healthcare reform in the U.S.There are about 47 million people in the U.S. who do not have healthcarecoverage. And that number grows every year.We believe the country must come together on this issue and we supportbipartisan healthcare reform that will ensure access to affordable healthcarecoverage for all Americans.
  • 13. 13We are hopeful that our participation in the healthcare reform process and oursupport for specific policies will help generate solutions that provide affordablehealth insurance coverage for all. INNOVATIONInnovation is the lifeblood of Merck. That is why we invested almost $5 billion inresearch and development activities in 2008. Yet investment alone is not enough toguarantee success.Drug research is a high-risk and time-consuming process. Only 1 out of every5000-10,000 compound screened becomes an approved drug. It takes an averageof 10 to 15 years at an average cost of more than US$1 billion to develop asuccessful medicine.1To deliver important products to the people who need them, we need a globalenvironment that supports the following enabling factors:  Intellectual Property Protection  Competition-based Healthcare  Government Support for Basic Biomedical Research  Evidence-based Regulatory Environment  Global Business Environment QUALITY & SAFETYFrom research and development to the manufacturing and distribution of ourmedicines, vaccines and other products, safety and quality are our firstconsiderations.We are committed to manufacturing quality products and demand equivalentstandards from our suppliers to help ensure patient safety.Some of our quality and safety systems include:  Quality standards: We maintain policies, processes and procedures to help ensure product quality.
  • 14. 14  Quality systems: Our global quality systems, made up of policies, processes and procedures, are designed to ensure consistent product quality worldwide.  Education and training: We provide ongoing education and training programs on quality and cGMP and on Good Clinical Practice (GCP) for our employees.  Supplier standards: We maintain strict quality standards and insist on the same from our suppliers and licensees, regardless of their location.  Adverse event reporting: We maintain an Adverse Event Reporting database and global procedures to compile adverse event information and ensure compliance regulations globally.  Safety monitoring: We have developed processes and procedures for the timely and accurate monitoring of the safety profiles of our investigational and marketed products. SALES & MARKETINGWe know that doctors and patients look to us to provide accurate and balancedinformation about our products. We adhere to strict ethical sales and marketingpractices for all of our businesses, whether pharmaceuticals, vaccines, consumerhealth or animal health.We believe direct-to-consumer (DTC) advertising contributes to greater awarenessabout conditions and diseases, which can benefit public health by increasing thenumber of patients appropriately diagnosed and treated.Our interactions with healthcare providers, other customers and consumers aregoverned by laws and regulations, and by our global code of conduct whichincludes standard business practices and compliance guidance. We take theseresponsibilities seriously and periodically evaluate our marketing, sales andadvertising activities to ensure they align with the applicable laws, regulations andMercks policies and values. RESPONSIBLE PUBLIC POLICY AND ADVOCACYMerck is committed to participating constructively and responsibly in the politicalprocess. Government proposals to regulate the health care system may directly
  • 15. 15affect the companys business and incentives for pharmaceutical innovation. Also,there are important policy initiatives that can further the companys goals withrespect to increasing patient access to medicines and vaccines -- particularly forpatients in disadvantaged communities and regions -- and, most importantly, tohealth care insurance coverage. It is appropriate for the company to help informthe debate on these issues in the United States and in other countries, and to doso in a responsible and ethical way. ACCESSWe discover and develop medicines and vaccines for millions of people around theworld. But that’s not enough if people can’t access them.We know that not everyone who needs our medicines and vaccines can get them –whether because of an inability to see a doctor for a diagnosis or to pay for aneeded treatment.In the United States, we are working to support much-needed reform of thecountry’s healthcare system so people have insurance coverage. In the meantime,we continue to make available and enhance our Patient Assistance Program so theuninsured can receive our medicines and vaccines for free.In other parts of the world, we have created numerous programs and public/privatepartnerships to help improve healthcare capacity and improve access to ourproducts so all can benefit, wherever they live. ENVIRONMENTWe at Merck remain dedicated to being environmentally responsible in how wemanufacture our medicines and vaccines. And we work hard to reduce ourenvironmental impact through stewardship of natural resources like water, byconserving energy and also by appropriately eliminating waste.We also go beyond the direct impact of our business to positively influence theenvironment. Our main way of doing so is through financial support of non-governmental organizations and their local partners to protect ecological resourcesaround the world.
  • 16. 16 DISCOVERY AND DEVELOPMENTThe work we do in our labs has helped to save and improve countless lives.Thanks to our world-class researchers, state-of-the-art technologies andunrelenting focus on scientific excellence, Merck is at the forefront of discoveringand developing new ways to treat and prevent disease.Scientific discovery and development have always been the cornerstones of ourcompany. Today, we conduct research in a broad range of therapeutic categories –including cardiovascular disease, infectious diseases, vaccines, cancer, neurologyand women’s health. And, to help achieve our goal of saving and improving livesaround the world, we are expanding our capabilities in new areas, such asbiologics. COMMUNITY: FIGHTING HIV/AIDSWorking in Partnership against HIV/AIDSIn 2000, in response to the massive threat HIV and AIDS posed in the sub-Saharan nation of Botswana, Merck joined with the Government of Botswana andthe Bill & Melinda Gates Foundation to form the African Comprehensive HIV/AIDSPartnerships. The Merck Company Foundation committed an initial $56.5 million tothe partnership to provide treatment, care and support for people living with HIVand AIDS, as well as to help prevent its further spread. In addition, Merck agreedto donate its antiretroviral medicines to Botswanas national antiretroviral treatmentprogram for the partnerships duration.The partners selected Botswana because it had one of the highest adultprevalence rates of HIV and AIDS in the world, a viable existing healthcareinfrastructure and strong political will and commitment to address the challenges ofHIV and AIDS.In 2007, ACHAP expanded its support to target co-infection of HIV andtuberculosis (TB). HIV infection has fueled an explosive increase in TB cases inBotswana since the early 1990s.Building on the successes created by its initial investment, in 2010 Merckcontributed an additional $30 million over the next five years. The new funding willcontinue the programs original efforts in treatment and care but also will supportthe second phase initiatives to meet the current treatment needs of the 137,000
  • 17. 17Batswana (people from Botswana) living with HIV and new patients enrolled in thesecond phase. The second phase initiatives include: the prevention of HIV.Report from the United Nations about the AIDS in the 2010 Sources: elmundo.es
  • 18. 18Graphic No. 1: The number of people surviving with HIV continues toincrease due to life-prolonging treatments Sources: CINUBetween 2004 and 2009, the number of people receiving antiretroviral treatmentfor HIV or AIDS was multiplied by 13. As a result, deaths from this disease duringthis period decreased by 19%. In addition to fewer new infections, infected peoplelive longer.In 2009 there were 33.3 million people living with HIV, 27% more than in 1999.Sub-Saharan Africa remains the region most affected: it has 69% of new HIVinfections, 68% of all HIV-positive population and 72% of AIDS deaths. However,the epidemic has spread to other regions.
  • 19. 19Graphic No. 2: Treatment for HIV and AIDS is widespread, but not enoughto meet the goal of universal access by 2010 Sources: CINUIn late 2009, in countries with low and middle income had 5.25 million peoplereceiving antiretroviral therapy. This represents an increase of more than 1.2million people compared to December 2008, which saw the largest annual increaseever recorded.Some countries, including Botswana, Cambodia, Croatia, Cuba, Guyana, Oman,Romania and Rwanda, have already achieved universal access (defined ascoverage of at least 80% of the population in need) to antiretroviral treatment and /or interventions prevent HIV transmission.The World Health Organization (WHO) revised its guidelines in 2009 regarding thetreatment of HIV-positive adults and adolescents, including pregnant women. As a
  • 20. 20result, the number of people needing antiretroviral therapy defined increased from10.1 to 14.6 million in late 2009.Graphic No. 3: Work is progressing steadily in reducing HIV transmissionto newborns Sources: CINUWithout treatment of the mother, about one third of children of HIV positive womenwill become infected with the virus during pregnancy, childbirth or breastfeeding.This risk can be greatly reduced if the pregnant woman is treated with antiretroviraltherapy.In 2009, the number of HIV positive pregnant women receiving antiretroviraltherapy treatment was 53%, which only reached 45% in 2008. About 91% of the1.4 million pregnant women needing treatment live in sub-Saharan Africa.
  • 21. 21 CONSUMER PRODUCTSThrough our consumer health products, we strive to enhance the quality of life forpeople and their families around the world.Each day, millions count on one or more of our industry-leading brands that helpprevent or treat various common conditions.There are the most important and effectly product that we have to control thehuman immunodeficiency virus (AIDS), which are:1. ISENTRESS® ISENTRESS is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI); an anti-HIV (antiretroviral) medicine used for the treatment of HIV. This medicine works blocking an enzyme called HIV integrase which the virus (HIV) needs in order to make more virus. Isentress is used in the mayority of cases with other anti-HIV medicines to reduce the amount of the Human Immunodeficiency Virus (HIV) in the blood and increase the number of white blood cells. INGREDIENTS Active ingredient: Each film-coated tablet contains 400 mg of raltegravir. Inactive ingredients: Microcrystalline cellulose, lactose monohydrate, calcium phosphate dibasic anhydrous, hypromellose 2208, poloxamer 407 (contains 0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate, magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc, red iron oxide and black iron oxide.
  • 22. 222. CRIXIVAN® CRIXIVAN is an oral capsule used for the treatment of HIV (Human Immunodeficiency Virus). HIV is the virus that causes AIDS (acquired immune deficiency syndrome). CRIXIVAN is a type of HIV drug called a protease (PRO- tee-ase) inhibitor. CRIXIVAN is a protease inhibitor that fights HIV. CRIXIVAN can help reduce your chances of getting illnesses associated with HIV. CRIXIVAN can also help lower the amount of HIV in your body (called “viral load”) and raise your CD4 (T) cell count. CRIXIVAN may not have these effects in all patients. CRIXIVAN is usually prescribed with other anti-HIV drugs such as ZDV (also called AZT), 3TC, ddI, ddC, or d4T. CRIXIVAN works differently from these other anti-HIV drugs. Talk with your doctor about how you should take CRIXIVAN. CONCLUSIONFrom this document we can observer that MERCK is an important and recognizedcompany that has a good position in the global pharmaceutical market and hasbeen involved in the discovering of infinitive of medicines to improve the humanand animal health.MERCK is one of the most interested in help to save the humans from illnessesthat are destroying them; one example of this is the donation o medicine to controlthe AISD and the intervention on the healthcare reform in The United States toimprove the human welfare and reduce de mortality rate.In summary and to end we can say that MERCK with its discovers and thought tothe future could be a excellent group with the government of each countryinterested in improve the human welfare to try of raising all their projects together.
  • 23. 23 REFERENCES- Source: Merck be well http://www.merck.com/about/Merck%20Corporate%20Ads.pdf, retrieved on September 24 of 2011.- Source: CIRU “Centro de Información de las Naciones Unidas” http://www.cinu.mx/minisitio/ODM2011/docs/InformeODM2011.pdf, retrieved on October 03 of 2011.- Sources: elmundo.es http://www.elmundo.es/elmundosalud/documentos/2010/11/onusida/est_mundo _2010.html, retrieved on October 05 of 2011.- Sources: MSD http://www.msd.com.co/msdco/corporate/index.html, retrieved on October 05 of 2011.- Sources: The Merck group http://www.merckgroup.com/en/index.html, retrieved on October 06 of 2011.- Sources: Merck http://www.merck-chemicals.com/, retrieved on October 06 of 2011.- Sources: The Merck manual http://www.merckmanuals.com/professional/index.html, retrieved on October 06 of 2011.- Sources: The sacramento bee http://www.sacbee.com/2011/10/05/3961844/hivaids-therapeutics-market- to.html, retrieved on October 06 of 2011.

×